Identifying autoantigens as theranostic targets: Antigen arrays and immunoproteomics approaches

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 2, 2008, Pages 107-115

  Tassinari, O W ^a   Caiazzo Jr , J R ^a   Ehrlich, J R ^a   Liu, B C S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

AMIDA; Reverse capture; SEREX; SERPA; Theranostics

Indexed keywords

AUTOANTIGEN; COMPLEMENTARY DNA;

ANTIGEN ANTIBODY REACTION; GENE EXPRESSION; MICROARRAY ANALYSIS; MOLECULAR CLONING; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SEROLOGY;

AUTOANTIGENS; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DNA, RECOMBINANT; HUMANS; IMMUNOTHERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS;

EID: 41849143435     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Booth RA: Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett (2007) 249(1):87-96.
2. Warner S: Diagnostics + Therapy = Theranostics. The Scientist (2004) 18(16):38. • A brief introduction to theranostics, discussing current theranostic strategies, pharmaceutical involvement, and the future directions of this field, is provided.
3. Gale HB, Kan VL, Shinol RC: Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin Vaccine Immunol (2006) 13(2):235-238.
4. Hanna GJ, D'Aquila RT: Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis (2001) 32(5):774-782.
5. A breakthrough in individualized treatment: Individualized drug dosing based on metabolic profiling with the AmpliChip CYP450 test. Roche Diagnostics, Indianapolis, IN, USA (2006). http://www.amplichip.us/
6. Taegtmeyer AB: Personalized medicine. McGill J Med (2007) 10(1):51-52.
7. New Device Approval: DakoCytomation c-Kit pharmDx - P040011. FDA, Center for Devices and Radiological Health, MD, USA (2005). http://www.fda. gov/cdrh/mda/docs/p040011.html
8. Nelson NJ: Experts debate value of HER2 testing methods. J Natl Cancer Inst (2000) 92(4):292-294.
9. Caiazzo RJ Jr, Tassinari OW, Ehrlich JR, Liu BC: Autoantibody microarrays for biomarker discovery. Expert Rev Proteomics (2007) 4(2):261-272.
10. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA (1995) 92(25):11810-11813. •• One of the first studies to describe the use of SEREX for the identification of tumor associated antigens.
11. Türeci O, Sahin U, Pfreundschuh M: Serological analysis of human tumor antigens: Molecular definition and implications. Mol Med Today (1997) 3(8):342-349.
12. Gunawardana CG, Diamandis EP: High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett (2007) 249(1):110-119.
13. Li G, Miles A, Line A, Rees RC: Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother (2004) 53(3):139-143.
14. Cancer immunome database: Ludwig Institute for Cancer Research, New York, NY, USA (2008). http://ludwig-sun5.unil.ch/CancerImmunomeDB
15. Lim Y, Lee DY, Lee S, Park SY, Kim J, Cho B, Lee H, Kim HY, Lee E, Song YW, Jeoung DI: Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun (2002) 295(1):119-124.
16. Uchida K, Akita Y, Matsuo K, Fujiwara S, Nakagawa A, Kazaoka Y, Hachiya H, Naganawa Y, Oh-Iwa I, Ohura K, Saga S et al: Identification of specific autoantigens in Sjögren's syndrome by SEREX. Immunology (2005) 116(1):53-63.
17. Jeoung DI, Bong Lee E, Lee S, Lim Y, Lee DY, Kim J, Kim HY, Wook Song Y: Autoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosis. Biochem Biophys Res Commun (2002) 299(4):549-554.
18. Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X, Li X, Yi H, Li M, Zhu G, Liang S: Proteome analysis of human lung squamous carcinoma. Proteomics (2006) 6(2):547-558. • The use of serological proteome analysis (SERPA) for the identification of tumor associated antigens is described.
19. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B: Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics (2002) 2(12):1743-1751.
20. Caron M, Choquet-Kastylevsky G, Joubert-Caron R: Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics (2007) 6(7):1115-1122.
21. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B: Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta (2003) 1646(1-2):21-31. • The use of PROTEOMEX for the identification of cancer sera immunoreactivity is described.
22. Gires O, Münz M, Schaffrik M, Kieu C, Rauch J, Ahlemann M, Eberle D, Mack B, Wollenberg B, Lang S, Hofmann T et al: Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology. Cell Mol Life Sci (2004) 61(10):1198-1207. • One of the first studies to describe the development and use of AMIDA for the identification of disease-associated antigens.
23. Rauch J, Ahlemann M, Schaffrik M, Mack B, Ertongur S, Andratschke M, Zeidler R, Lang S, Gires O: Allogenic antibody-mediated identification of head and neck cancer antigens. Biochem Biophys Res Commun (2004) 323(1):156-162. •• One of the first studies to describe the development and use of an allogenic variant of AMIDA (allo-AMIDA).
24. Gires O, Mack B, Rauch J, Matthias C: CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck. Biochem Biophys Res Commun (2006) 343(1):252-259.
25. Kingsmore SF: Multiplexed protein measurement: Technologies and applications of protein and antibody arrays. Nat Rev Drug Discov (2006) 5(4):310-320.
26. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW et al: Autoantibody signatures in prostate cancer. N Engl J Med (2005) 353(12):1224-1235. •• One of the first studies to describe the use of phage-protein microarrays for the autoantibody profiling of prostate cancer.
27. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K et al: Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 8(3):295-301. •• One of the first studies to describe the use of antigen microarrays for autoimmune diseases.
28. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sønderstrup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ et al: Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum (2005) 52(9):2645-2655.
29. Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold LA, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D, Omenn GS et al: Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics (2003) 3(11):2200-2207. •• One of the first studies to describe the development and use of native antigen microarrays to investigate cancer serum immunoreactivity.
30. Qin S, Qiu W, Ehrlich JR, Ferdinand AS, Richie JP, O'Leary MP, Lee ML, Liu BC: Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics (2006) 6(10):3199-3209. •• One of the first studies to describe the development and use of the 'reverse-capture' autoantibody microarray platform for autoantibody profiling.
31. Ehrlich JR, Qin S, Liu BC-S: The 'reverse capture' autoantibody microarray: A native antigen-based platform for autoantibody profiling. Nat Protocols (2006) 1(1):452-460. • A detailed protocol of the 'reverse-capture' autoantibody microarray platform is described.
32. Ehrlich JR, Caiazzo RJ, Qiu W, Tassinari OW, O'Leary MP, Richie JP, Liu BC-S: A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera. Proteomics - Clinical Applications (2007) 1(5):476-485.
33. Katoh M: Bioinformatics for cancer management in the postgenome era. Technol Cancer Res Treat (2006) 5(2):169-175.
34. Genomics and bioinformatics group: Laboratory of Molecular Pharmacology, National Institutes of Health, Bethesda, MD, USA (2008). http://discover.nci.nih.gov/